NeuroEM

11/11/2025

Thanks to all who serve.

11/11/2025

From everyone at NeuroEM, thank you to all who serve.

11/03/2025

Introducing Patty Meagher, our Alzheimer’s Community Advocate who has served as a strategic advisor to NeuroEM in various roles since our earliest days.

Her interest in finding a treatment for the cognitive decline caused by Alzheimer’s is deeply personal–Patty's mother participated in an early safety trial. That experience revealed the potential of our TEMT-RF headset and further inspired her dedication to getting this groundbreaking device into the hands of everyone affected by Alzheimer’s—and anyone interested in maintaining their brain health.

Patty Meagher is a seasoned investor and startup advisor with 20+ years in venture capital and technology. A founding leader in Connecticut’s innovation ecosystem, she’s helped startups raise over $200M and now advocates for Alzheimer’s awareness and innovation.

10/13/2025

"Introducing … NeuroEM’s head of Device R&D Rob Baranowski, who's bringing 30+ years of product design expertise to ensure our groundbreaking TEMT-RF headset for brain health is ready for commercial debut. Early clinical trials show promising results indicating that this device may actually prevent and even reverse cognitive decline associated with aging.

Rob, who led several cellular R&D and design programs at Motorola and Sony, founded Left Coast Engineering in 1999 to develop the first location-aware app. He has since grown LCE’s focus into custom electronic and mechanical product development, supporting more than 250 new products into production with design-for-manufacturability for medical, industrial, commercial and government applications. https://www.linkedin.com/in/lcerob/

10/03/2025

Technology is reshaping how we approach dementia risk reduction.

A new multinational RCT led by Finnish researchers explores a digitally supported multimodal lifestyle intervention for older adults at risk of cognitive decline. The LETHE trial combines in-person sessions with digital tools—smartphones, smartwatches, mobile apps, and even interactive tech like audio glasses and social robots—to personalize care, streamline delivery, and collect digital biomarkers.

As the study authors note, “Digital tools specifically designed for older adults could offer potential for large-scale, cost-effective prevention programs.”

This hybrid model doesn’t just enhance engagement—it generates rich data on usability, adherence, and perceived value, offering insights into how older adults interact with tech in the context of brain health. The trial’s design also opens the door to new hypotheses about early mechanisms of cognitive decline.

For those of us working at the intersection of health IT, aging, and neurodegeneration, this is a compelling signal: scalable, tech-enabled prevention is within reach.

📄 Read the full study on Alzheimer’s Research & Therapy | https://ow.ly/Ky3z50X6tEv

10/01/2025

Two -approved cancer drugs—letrozole & irinotecan—reversed Alzheimer’s-related brain damage in mice, restoring memory by targeting gene expression & toxic tau buildup. |

In efforts to beat Alzheimer's disease, researchers are looking at existing drugs that could tackle the condition, and a new study identifies two promising candidates that are currently used to treat cancer.

09/19/2025

The push for “transformative treatments” echoes U.S. Food and Drug Administration Commissioner Makary’s priority to accelerate innovative therapies to market—aligning with recent comments from Kennedy and others. https://ow.ly/jekV50WZp7b

09/12/2025

As we look ahead to the commercial launch of our next-gen TEMT-RF headset - demo’d here by our CEO - we’re grateful to groups like the Big Idea CONNECTpreneur Forum for giving us a platform that will help us advance from groundbreaking research to a commercially viable reality.

09/12/2025

At the Big Idea CONNECTpreneur Forum, CEO Chuck Papageorgiou shared with attendees info on our TEMT-RF headset, demonstrating the prototype used in early clinical trials showing its effectiveness at stopping and reversing cognitive decline from Alzheimer’s…without drugs.

09/12/2025

It was an eventful day yesterday at the Big Idea CONNECTpreneur Forum — the world’s largest monthly investor pitch — where we had the opportunity to share how NeuroEM’s TEMT-RF is on the cusp of revolutionizing the treatment of cognitive decline.

👉 Follow for more highlights from the day!👈

09/12/2025

Chuck also shared with the top business leaders, angels, and private investors at the Big Idea CONNECTpreneur Forum how NeuroEM’s breakthrough TEMT-RF headset is redefining brain health and stopping and reversing cognitive decline from Alzheimer’s without drugs.

09/12/2025

Chuck took to the Big Idea CONNECTpreneur Forum stage to discuss how we are advancing our TEMT-RF technology from groundbreaking research to a commercially viable reality.